Detalhe da pesquisa
1.
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
N Engl J Med
; 390(6): 497-509, 2024 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38324483
2.
Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis.
Gastroenterology
; 160(1): 219-231.e1, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32781086
3.
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet
; 394(10213): 2012-2024, 2019 11 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-31727409
4.
Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial.
Nat Med
; 29(11): 2919-2928, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37845512
5.
Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial.
Lancet Gastroenterol Hepatol
; 7(7): 603-616, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35325622
6.
Effects of Resmetirom on Noninvasive Endpoints in a 36-Week Phase 2 Active Treatment Extension Study in Patients With NASH.
Hepatol Commun
; 5(4): 573-588, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33860116